Vivani Medical (NASDAQ:VANI) Releases Earnings Results, Beats Estimates By $0.01 EPS

Vivani Medical (NASDAQ:VANI) announced its earnings results on Thursday. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.01, FiscalAI reports.

Vivani Medical Stock Down 4.4%

Shares of VANI traded down $0.05 during midday trading on Thursday, reaching $1.08. 270,967 shares of the stock were exchanged, compared to its average volume of 314,627. Vivani Medical has a 12-month low of $0.91 and a 12-month high of $1.92. The firm has a 50 day simple moving average of $1.26 and a 200-day simple moving average of $1.36. The company has a market cap of $84.42 million, a price-to-earnings ratio of -2.40 and a beta of 3.17.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Vivani Medical in a report on Friday, January 9th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $4.00.

Insider Activity at Vivani Medical

In other news, Director Gregg Williams acquired 1,575,231 shares of the company’s stock in a transaction that occurred on Sunday, March 15th. The shares were purchased at an average price of $1.07 per share, for a total transaction of $1,685,497.17. Following the completion of the acquisition, the director owned 31,357,183 shares of the company’s stock, valued at approximately $33,552,185.81. This represents a 5.29% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Over the last three months, insiders purchased 4,664,347 shares of company stock valued at $5,666,549. Insiders own 46.40% of the company’s stock.

Hedge Funds Weigh In On Vivani Medical

Institutional investors have recently modified their holdings of the company. Tudor Investment Corp ET AL bought a new stake in shares of Vivani Medical during the fourth quarter valued at approximately $1,127,000. Geode Capital Management LLC increased its position in shares of Vivani Medical by 29.6% during the 4th quarter. Geode Capital Management LLC now owns 461,652 shares of the company’s stock worth $568,000 after purchasing an additional 105,398 shares in the last quarter. State Street Corp raised its stake in shares of Vivani Medical by 12.5% in the fourth quarter. State Street Corp now owns 144,865 shares of the company’s stock valued at $178,000 after acquiring an additional 16,070 shares during the last quarter. Marshall Wace LLP bought a new position in Vivani Medical in the 4th quarter valued at $174,000. Finally, Renaissance Technologies LLC raised its holdings in shares of Vivani Medical by 118.4% in the fourth quarter. Renaissance Technologies LLC now owns 97,985 shares of the company’s stock valued at $121,000 after buying an additional 53,127 shares during the last quarter. Institutional investors own 6.78% of the company’s stock.

Vivani Medical Company Profile

Vivani Medical Solutions, Inc (NASDAQ: VANI) is a medical technology company focused on the design, development and commercialization of advanced specimen retrieval and hemostasis products for minimally invasive diagnostic procedures. Its core mission is to enhance procedural safety and streamline clinical workflows for interventional radiologists and pathology laboratories.

The company’s flagship offerings include the StopBleed Retrieval Device and StopBleed Pad, which integrate proprietary hemostatic materials to control bleeding at biopsy sites and preserve tissue integrity.